Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ablynx receive $3 million from Wyeth collaboration

This article was originally published in Scrip

Executive Summary

Ablynx has received $3 million from Wyeth after the US company started the first Phase I study in healthy volunteers for a nanobody against TNF-alpha. The two firms signed, and have since extended, a deal worth up to a potential $212.5 million to discover, develop and commercialise Ablynx's proprietary anti-TNF-alpha nanobodies (Scrip Online, December 20th, 2007). Nanobodies are a novel class of therapeutic proteins based on single-domain antibody fragments. Wyeth has exclusive rights to develop and commercialise the antibodies developed under the collaboration. Earlier this week the Belgian firm initiated a Phase I study in healthy volunteers with ALX-0681, an antithrombotic nanobody targeting the von Willebrand Factor. Ablynx is developing the nanobody for thrombotic thrombocytopenic purpura, but it could also have potential in unwanted blood-clot formation not addressed by intravenous administration. Results from a Phase Ib study of another antibody targeting the von Willebrand Factor, ALX-0081, are expected in the new year.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts